Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr
Gilead Sciences (NASDAQ: GILD) Delayed: 150.11 -0.78 (0.52%)
Previous Close $150.89    52 Week High $108.63 
Open $150.56    52 Week Low $71.39 
Day High $153.23    P/E 82.93 
Day Low $149.57    EPS $1.81 
Volume 16,453,710       

Merck & Co. (NYSE: MRK) Delayed: 146.87 -0.28 (0.19%)
Previous Close $147.15    52 Week High $65.46 
Open $147.08    52 Week Low $47.97 
Day High $147.84    P/E 99.91 
Day Low $145.74    EPS $1.47 
Volume 31,159,364